Asylia Therapeutics

HOUSTON, July 22, 2021 – Asylia Therapeutics (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of prominent experts and thought leaders in immunology and cancer biology. The formation of the SAB reflects significant progress with Asylia’s clinical …

Asylia Announces Formation of Distinguished Scientific Advisory Board Read More »

Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into treatable “hot” tumors, with the goal of enhancing effectiveness of cancer immunotherapy. Houston, May 25, 2021 – Asylia Therapeutics, Inc. (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the closing of a $14.5 …

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing Read More »

Houston, Texas. February 8, 2021 – Houston: the true third coast of innovation. Texas is home to more than 5,400 life science R&D and manufacturing firms, with more than 106,000 workers employed in related fields (THBI). As one of the top global biotechnology hubs, and home to the largest medical center in the world (Texas …

JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System Read More »

Houston, Texas. June 6, 2020 – Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and infectious diseases has officially landed at Johnson & Johnson Innovation – JLABS in the Texas Medical Center (JLABS @ TMC). With over 34,000 square feet of common, wet lab, and …

Asylia Therapeutics Moves into JLABS @TMC Read More »

Houston, Texas.  May 11, 2020 – Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and infectious diseases, today announced it has received a $3 million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas (CPRIT). Asylia will use the …

CPRIT Awards $3 Million to Asylia Therapeutics Read More »

The attached article demonstrates a key role for tumor-derived HSP70 in the development of robust anti-tumor immune responses. The results validate HSP70 as a target for the development of a novel class of immunomodulatory drugs, which is the focus of the Asylia platform. Learn More Published by Oncogene; March 14, 2014